Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (282)	3/18/1999 11:13:00 AM
From: aknahow	Read Replies (2) \| Respond to of 3158

Don't think what the chairman thinks matters in any case where significant shares are not controlled by management. Much more important might be will the intellectual core people stay or leave. I think mergers in this industry, below first tier, are much more difficult than resource company mergers or even drug company mergers where sales and assets are at least of some interest. When there are no sales or earnings why merge? Partnering would still seem to be the better option. Yes, the IBD "biotech" group is composed of 178 companies. Even so many third tier are up over 100% from their lows, irregardless of their still being down 50% from our cost. <g> Not, really deceiving in terms of identification of or branding a group hot. Many momentum players will come in only when this sector moves much higher in these rankings. At that time many of these players probably won't care much about the fundamentals. These are just thoughts, I obviously don't understand what is going on, starting with why intentions are announced.